Bladder, Kidney, Ureter, Urethra Flashcards

1
Q

Tacrolimus

A
  • Calcineurin inhibitor
  • More potent than cyclosporine
  • Used to prevent kidney graft rejection
  • But, also potentially nephrotoxic and can cause AKI
    • Same is true for other calcineurin inhibitors
  • Side effects include:
    • Nephrotoxicity
    • Hyperkalemia
    • HTN
    • Glucose intolerance (diabetogenicity)
    • Neurotixicity
    • Hypomegnesemia
    • CNS symptoms (headaches, tremors, seizures)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Etiology of uremic platelet dysfunction

A
  • In uremia, urea accumulates
  • In the setting of elevated urea, some ammonia is instead converted to guanidinosuccinic acid (GSA)
  • GSA then accumulates and, given its similarity to L-arginine, is used to produce NO
  • NO causes both venodilation and direct inhibition of paletlet adhesion and aggregation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Definition of chronic renal failure

A
  • Kidney damage of > 3 months duration
  • AND/OR GFR < 60 mL/1.73 m2/min
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

CKD stages

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Induction immunosuppression

A

Anti-thymocyte globulin is typically used, which is a mixture of polyclonal IgG against CD2, CD3, CD4, CD25, among others

Alternatively, daclizumab or basiliximab (monoclonal anti-IL2R antibodies) may be utilized. These new agents hvae early data suggesting lower rejection rates than polyclonal anti-thymocyte globulin.

Alemtuzumab (monoclonal antobidy against CD-52) has also been used off-label for induction therapy and in treatment of acute graft rejection.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Cyclosporine

A
  • Calcineurin inhibitor
  • Inhibits IL-2 production and thus T cell proliferation
  • Side effects:
    • Nephrotoxicity
    • Hypertension
    • Gingival hyperplasia
    • Hyperkalemia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Serolimus

A
  • aka Rapamycin
  • Targets mTOR
  • Less nephrotoxic than cyclosporine A and tacrolimus, but has other side effects:
    • Thrombocytopenia
    • Hyperlipidemia
    • Poor wound healing
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Dietary considerations for CKD

A
  • Really only become relevant when GFR approaches ~20
  • Potassium:
    • Dietary potassium restriction is sufficient to avoid hyperkalemia
  • Phosphorus:
    • Must be controlled to avoid secondary and tertiary hyperparathyroidism, as well as uncontrolled metabolic acidosis
    • Methods include
      • Dietary phosphate restriction
      • Phosphate binders
      • Administration of synthetic 1-25-OH-D
      • Subtotal parathyroidectomy (if full 2o or 3o hyperparathyroid)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

LVH in CKD

A
  • Two major stimuli:
    • Hypertension
    • Anemia
      • Anemia may actually be the more potent stimulus in untreated CKD. Treating anemia aggressively with EPO helps to prevent LVH.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Features of uremic neurological dysfunction

A
  • Uremic encephalopathy
    • A form of delirium comparable to hepatic encephalopathy
    • Also with asterixis
  • Uremic peripheral neuropathy
    • Motor: motor neuron dysfunction
    • Sensory: sensory impairment
    • Autonomic: Often manifests as postural or persistent hypotension in patients on dialysis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Classification of hemodialysis catheters

A
  • Temporary access (days)
  • Intermediate-term access (weeks-months)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

For critically ill hospitalized patients with uremia without other access, ___ to establish access is rapid and safe.

A

For critically ill hospitalized patients with uremia without other access, cannulation of the femoral vein to establish access is rapid and safe.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

___ are generally not utilized for hemodialysis catheter placement due to high risk of thrombosis and subsequent stenosis

A

Subclavian veins are generally not utilized for hemodialysis catheter placement due to high risk of thrombosis and subsequent stenosis

Note: This is so bad because it also eliminates this arm for future arterial-venous fistula creation for future dialysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Brescia-Cimino fistula

A
  • Artificial fistula created between the radial artery and cephalic vein in the non-dominant wrist
  • # 1 procedure for establishment of AVF for long-term hemodialysis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Advantages of AV fistula over AV graft

A

AVF is lower risk of infection and has a longer average lifespan than AVG

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

In the US, patients are considered for dialysis when their GFR falls below. . .

A

. . . 20 mL/min/1.73m2

17
Q

Living donor kidney transplant survival rate at 10 years is approximately. . .

A

. . . 50%

18
Q

Table of immunosuppressive medications for transplant medicine

A
19
Q

Standard maintenance immunosuppression therapy regimen

A
  • Combination of:
    1. Calcineurin inhibitor OR Serolimus
    2. Steroid
    3. Antiproliferative agent:
      • azathioprine
      • mycophenylate mofetil
20
Q

Symptoms of acute kidney graft rejection

A
  • Occurs w/in first few weeks-months following transplant
  • Fever, malaise, HTN, oliguria, weight gain, AKI
  • Tenderness over transplanted kidney
  • Confirm with biopsy
  • Tx with high dose steroids or monoclonal antibodies
21
Q

Infections in the peritransplant period

A
  • Account for 50% of the mortality during this period
  • Common etiologies:
    • PCP pneumonia
    • Aspergillus
    • Toxoplasma
    • Cryptococci
    • Bocardia
    • Blastomycosis
  • PPx against PCP pneumonia with bactrim
22
Q

Post-transplant lymphoproliferative disorder is best treated by. . .

A

. . . letting up on the immunosuppression by a bit

23
Q

Most common post-transplant malignancies

A
  • Mostly viral related
    • Lymphoproliferative disorders associated with CMV, EBV
    • Kaposi sarcoma (HHV8)
    • Squamous cell carcinoma and cervical cancer (HPV)
    • Hepatocellular carcinoma (Hep B and C)
24
Q

Chronic allograft nephropathy

A
  • Term for the nephropathy caused by the cumulative small insults to a kidney allograft
  • May represent micro-acute rejections, chronic rejection, infection, ischemia-reperfusion, and co-occurence of underlying nephropathies (diabetes, amyloid, HTN, etc)
  • There is no way to treat this condition, and it will eventually progress to late graft failure
25
Q

Clinically suspicious rejection episodes are treated . . .

A

. . . empirically when no other etiology is identified

However, a biopsy is often taken as it can be useful for confirmation. A negative biopsy should never be an argument against treatment, as false negative rate is high.

26
Q

Extended criteria donor

A
  • Kidney donor who:
    • Has age > 60
    • Has age 50-60 with history of HTN, DM, increased serum creatinine, or death from stroke
27
Q

Typical kidney donor criteria

A
  • Age 3-60
  • No history of HTN, DM, kidney disease, stroke
28
Q

HIV and kidney transplant recipients

A

HIV is no longer a contraindication to transplantation IF the patient is receiving HAART with CD4 > 200 reliably.

29
Q

Two major causes of mortality in the ESRD population

A
  • Infection
  • Dialysis access complication
30
Q

Dialysis can improve encephalopathy, metabolic function, and platelet function, but it cannot improve. . .

A

. . . immune function in CKD

31
Q

Median waitlist time for kidney transplant recipients in the US

A

~40 months

32
Q

ADPKD

A

Treatment is mostly supportive, but vaptans (V2 antagonsits) may slow disease progression